
Vical Inc. ( VICL ) Bank of America Merrill Lynch Health Care Conference Call May 15, 2012 01:00 pm ET Executives Vijay B. Samant – President
Vical Incorporated ( VICL ) Q1 2012 Earnings Call May 2, 2012, 12:00 a.m. ET Executives ..... Operator Operator Thank you and welcome ladies and gentlemen to the Vical Incorporated financial results conference call. (Operator Instructions
February on a small biotech company called Vical ( VICL ). At the time I thought it was a great high risk ..... Outperform" rating and a $5 price target on VICL . 4 additional catalysts for VICL which is trading at $3 a share: There is increasing
Vical ( VICL ): Q1 EPS of $0.00 beats by $0.07 . Revenue of $11.5M (+1816% Y/Y) beats by $9M . ( PR ) Post your comment!
By Brian Nichols : Over the last several months I have taken a particular interest in cancer stem cell therapies. The primary reason for my interest has been great results from a large number of candidates that are testing the boundaries of cancer treatment, with this therapy, in clinical trials.
By Bret Jensen : Thursday was a huge day for two of the biotech stocks in my portfolio. Gilead Sciences ( GILD ), which I have been positive on for some time , is up 14% after the company posted positive results from a 12-week study of its Hepatitis C treatment GS-7977. Human Genome Sciences ( HGSI
By Ganaxi Small Cap Movers : Micro-cap biotech stocks (those with market-caps of less than $300 million Complete Story »
By Theodore Cohen: Vical ( VICL ) announced today that researchers at Ehime University in Japan and their collaborators have developed a Vaxfectin-formulated
Vical ( VICL ) +2.9% premarket after announcing that researchers at a Japan university have developed a DNA vaccine candidate using its Vaxfectin adjuvant with the potential to prevent transmission of malaria. ( PR ) Post your comment!
By Kapitall : Do you worry that the market will see significant volatility in the near future? One idea is to consider a stock's historical correlation to volatility - stocks that are positively correlated may have been treated as safe havens. To illustrate this, we ran a screen on the biotech ...